Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 13 Nov 2026
Standard addition

Real-world characteristics, testing patterns, and outcomes in patients with tropomyosin receptor kinase fusion cancer from a large pooled clinicogenomic database

Delays between genetic testing and targeted treatment for TRK fusion cancer vary widely—uncovering this gap highlights a concrete opportunity to improve care speed.

Five clinicogenomic databases were pooled to describe care for 451 people with advanced TRK fusion cancer. The analysis found long delays between testing and targeted treatment and substantial variation in survival across tumor types.

What the study was

Study design
Pooled international real-world clinicogenomic cohort
Population
Patients with advanced or metastatic NTRK fusion cancers
Sample size
451
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
ESMO real world data and digital oncology

Why it surfaced

Large real-world evidence highlights an implementation gap in genomically targeted oncology without qualifying as a novel-treatment trial.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.